Key result
Early (<24 hours) high dose (80 mg of atorvastatin) statins may significantly reduce adverse cardiovascular outcomes and improve long-term mortality in acute coronary syndrome.
Why the study?
Does early high dose statin therapy reduce adverse cardiovascular outcomes and improve long-term mortality in patients with acute coronary syndrome?
Does early high dose statin therapy reduce adverse cardiovascular outcomes and improve long-term mortality in patients with acute coronary syndrome?
Early administration of high-dose statins (within 24 hours) in acute coronary syndrome may reduce adverse cardiovascular outcomes and improve long-term mortality.
Hypothesis-generating for early high-dose statins in ACS; leaves open need for RCTs before practice change.
In accordance with the recommendations of the American College of Cardiology/American Heart Association Joint Task Force, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are prescribed before hospital discharge after an episode of acute coronary syndrome. Yet, optimal timing and dosage have not been agreed upon. Recent evidence suggests a pleiotropic mechanism of action including vasoprotective, anti-inflammatory, and antiarrhythmic properties that imply an immediate role for statin medications. Our review suggests that early (<24 hours) high dose (80 mg of atorvastatin) statins may significantly reduce adverse cardiovascular outcomes and may improve long-term mortality.
No takes yet. Share an insight, caveat, or question.
Dougherty et al. (2012) conducted a review in Acute Coronary Syndrome. Early high dose statins (atorvastatin) was evaluated on Adverse cardiovascular outcomes and long-term mortality. Early (<24 hours) high dose (80 mg of atorvastatin) statins may significantly reduce adverse cardiovascular outcomes and improve long-term mortality in acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: